Diagnostic Code 7723 · 38 CFR §4.117
Acquired hemolytic anemia is a condition where the body destroys its own red blood cells faster than the bone marrow can replace them. Unlike inherited forms of hemolytic anemia (like sickle cell disease), acquired hemolytic anemia develops after birth due to external triggers. The immune system may mistakenly attack red blood cells (autoimmune hemolytic anemia), or the destruction may be triggered by infections, medications, toxins, or mechanical damage to blood cells. Symptoms include fatigue, weakness, jaundice (yellowing of the skin and eyes), dark urine, rapid heartbeat, shortness of breath, and an enlarged spleen. For veterans, acquired hemolytic anemia can result from autoimmune reactions triggered by infections contracted during deployment, reactions to medications prescribed during service, toxic chemical or environmental exposures, or as a complication of other service-connected conditions like lupus or lymphoma. The condition can be episodic with flare-ups and remissions, or chronic and persistent.
| Rating | Criteria |
|---|---|
| 0% | History of acquired hemolytic anemia that has fully resolved with stable hemoglobin and no ongoing hemolysis markers. No current treatment needed. |
| 10% | Mild chronic hemolysis with slightly reduced hemoglobin, manageable with monitoring or low-dose medication. Occasional fatigue that limits stamina but does not prevent daily activities. |
| 30% | Moderate hemolytic anemia requiring ongoing immunosuppressive medication (such as corticosteroids), with periodic flare-ups causing noticeable jaundice, increased fatigue, and need for dose adjustments or additional treatment. |
| 70% | Severe hemolytic anemia with frequent hemolytic episodes despite treatment, requiring high-dose immunosuppression or multiple drug regimens. Persistent moderate-to-severe anemia with substantial fatigue, recurrent jaundice, and limited ability to maintain employment. |
| 100% | Refractory hemolytic anemia requiring frequent transfusions, plasmapheresis, or splenectomy consideration despite maximum medical therapy. Life-threatening hemolytic crises and inability to sustain any meaningful daily activity. |
Lab work demonstrating hemolysis is the diagnostic cornerstone: elevated reticulocyte count (bone marrow trying to compensate), elevated bilirubin and lactate dehydrogenase (from red blood cell destruction), low haptoglobin, and a positive direct antiglobulin test (Coombs test) for autoimmune types. Serial CBC results showing the pattern of anemia are important. Treatment records documenting corticosteroids, immunosuppressive drugs, transfusions, or splenectomy demonstrate severity. If triggered by a medication, infection, or toxic exposure during service, medical records documenting the timeline and a nexus opinion connecting the trigger to service are needed.
Common triggers include autoimmune reactions (sometimes triggered by infections or stress), medications, toxic exposures, and complications of other conditions like lupus. The condition is called acquired because it develops from an external trigger rather than being inherited.
Yes. Splenectomy is rated at a fixed 20 percent under DC 7706, separate from the hemolytic anemia rating under DC 7723. Both ratings contribute to your combined disability percentage.